Lineage Cell Therapeutics (LCTX) H.C. Wainwright 4th Annual Ophthalmology Virtual Conference summary

Financial and operational overview

• Reported financial position of $38 million, supporting operations into Q4 next year.

• Workforce of about 75 employees, with a manufacturing facility in Israel.

• Partnership with Roche and Genentech includes a $670 million deal, with $50 million upfront.

• Expanded collaboration with Genentech, reflecting continued investment despite industry reprioritization.

Lead asset and clinical progress

• OpRegen, an RPE cell transplant for dry AMD, addresses a major unmet need with few effective therapies.

• Phase I study showed safety and no rejection in advanced patients; later cohorts showed vision improvement and retinal restoration.

• Patients with full coverage of transplanted cells gained 7+ letters of visual acuity at two years, a significant improvement over controls.

• Durable anatomical and functional improvements observed, with effects lasting years.

Manufacturing and technology platform

• Uses pluripotent cell lines for scalable, reproducible, and pure RPE cell production.

• Allogeneic, off-the-shelf approach enables cost efficiency and avoids repeated donor sourcing.

• Manufacturing process allows production of thousands of clinical courses from a single bioreactor.